Jade Biosciences (NASDAQ:JBIO) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
Jade Biosciences (NASDAQ:JBIO) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
Institutional investors in Jade Biosciences, Inc. (NASDAQ:JBIO) must be dismayed after prices dropped by 16% last week [Yahoo! Finance]
Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference